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Abstract As a pilot study to investigate whether personalized medicine approaches could have value for the reduction of
malaria-related mortality in young children, we evaluated questionnaire and biomarker data collected from the Mother
Offspring Malaria Study Project birth cohort (Muheza, Tanzania, 2002–2006) at the time of delivery as potential prognostic
markers for pediatric severe malarial anemia. Severe malarial anemia, deﬁned here as a Plasmodium falciparum infection
accompanied by hemoglobin levels below 50 g/L, is a key manifestation of life-threatening malaria in high transmission
regions. For this study sample, a prediction model incorporating cord blood levels of interleukin-1β provided the strongest
discrimination of severe malarial anemia risk with a C-index of 0.77 (95% CI 0.70–0.84), whereas a pragmatic model based
on sex, gravidity, transmission season at delivery, and bed net possession yielded a more modest C-index of 0.63 (95% CI 0.54–
0.71). Although additional studies, ideally incorporating larger sample sizes and higher event per predictor ratios, are needed
to externally validate these prediction models, the ﬁndings provide proof of concept that risk score-based screening pro-
grams could be developed to avert severe malaria cases in early childhood.
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Introduction
Although improved uptake of vector control measures and
ﬁrst-line antimalarial medication has reduced the number
of deaths due to malaria in children younger than 5 years
of age by nearly 60% since the year 2000, malaria still
remains the fourth leading cause of child death in
sub-Saharan Africa [1, 2]. In the Global Technical Strategy
for Malaria 2016–2030 endorsed in May 2015, the World
Health Assembly set the goal of reducing the 2015 malaria
mortality rates by a further 90% by 2030 [3]. Mathematical
models of Plasmodium falciparum transmission suggest that
scaling-up of existing population-wide interventions, includ-
ing through expanded access to long-lasting insecticidal nets
(LLINs), seasonal malaria chemoprevention in children aged
6 months to 5 years, and artesunate therapies, could reduce
malaria mortality rates by up to an estimated 74% (95% CI
67–84%) [4]. Further, the incorporation of ‘near-term inno-
vations,’ such as LLINs with four-year half-lives, broader use
of seasonal malaria chemoprevention in children aged 6–10
years, and the use of alternative chemopreventive medica-
tions in East African regions with high sulfadoxine-
pyrimethamine parasitic resistance, could lead to mortality
reductions of up to 81% (95% CI 76–87%) [4]. By using
population-level strategies that seek to control the causes
of malarial death, the proposed scenarios could potentially
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save millions of lives. Nevertheless, implementation of
these agendas will be highly costly and, barring develop-
ment of the near-term innovations, will fall short of achiev-
ing the 90% mortality reduction benchmark. Therefore,
we asked: Would it be feasible to complement the ‘popu-
lation approach’ with a ‘high-risk approach’ that aims to
provide additional targeted intervention to the children
who are most susceptible to developing life-threatening
malaria? [5]
Using data collected at the time of birth as part of the
Mother Offspring Malaria Study (MOMS) Project birth
cohort in Muheza, United Republic of Tanzania, between
2002 and 2006, we sought to develop a prognostic model
for severe malarial anemia as a pilot study for investigating
whether personalized medicine approaches could have
value for the reduction of malaria-related mortality. In
regions with high malaria transmission, severe malarial
anemia, here deﬁned as a P. falciparum infection with hemo-
globin concentrations below 50 g/L, is the most common
manifestation of life-threatening malaria in young children
[6]. Moreover, previous studies on this cohort provided evi-
dence that cord levels of the pro-inﬂammatory cytokines
tumor necrosis factor (TNF) and interleukin-1β (IL-1β)
may correlate with children’s cytokine levels throughout
infancy and may be inversely related to future parasite bur-
dens and severe malarial anemia risk [7, 8]. Building on this
research, we aimed to: (i) assess the discriminative ability of
subject characteristics and biological markers measured at
delivery for the prediction of a child’s probability of develop-
ing severe malarial anemia during the ﬁrst 3 years of life and
(ii) estimate the potential clinical beneﬁt of using a risk pre-
diction model to guide further intervention.
Methods
Study cohort
The study setting, location, dates, and methods for data col-
lection and follow-up in the MOMS Project have been
described in detail previously [9]. To be eligible for the
study, children had to be: (i) born to human immunodeﬁ-
ciency virus negative mothers, (ii) sickle cell disease free,
(iii) singleton births, and (iv) followed for a minimum of
28 days. The primary outcome was time to ﬁrst severe mal-
arial anemia. Clinical teams monitored children for severe
malarial anemia at all sick visits and during routine visits
occurring every 2 weeks in infancy and every 4 weeks there-
after until age 4 or study termination. Parasitemia was
assessed by Giemsa-stained thick blood smear, and hemo-
globin levels were measured with an impedance-based ana-
lyzer. The candidate predictors included: sex, genotypes for
beta-globin (i.e., AA and AS) and alpha-thalassemia (i.e., α/α,
α/α− 3.7, and α− 3.7/α− 3.7), birth weight, maternal age,
gravidity (i.e., here indicated by number of previous preg-
nancies), transmission season at delivery (i.e., early high
season (May–July), late high season (August–October),
early low season (November–January), and late low season
(February–April), placental malaria status at delivery (i.e.,
the detection of P. falciparum parasitemia in placental
blood collected through mechanical pressing of full-
thickness tissue), household bed net possession at delivery
(i.e., treated, untreated, and no/unknown), intermittent pre-
ventive treatment in pregnancy (IPTp) (i.e., 0 versus 1+
doses), and a panel of cord blood cytokines and receptors
listed in Table 1 and visualized in Supplementary Fig. S1.
Sickle cell trait was determined by cellulose acetate paper
electrophoresis (Helena Laboratories, Beaumont, TX,
USA). Alpha-thalassemia was determined by PCR [10].
Birth weight was evaluated within 24 h after delivery. Data
on maternal age, gravidity, household bed net possession,
and IPTp dosage were self-reported. Soluble cytokines and
receptors in cord blood plasma were measured using com-
mercially available multiplex, bead-based platforms
(BioPlex®, BioRad, Irvine, CA, USA) and custom-made
assay kits as previously described [11]. Samples that did
not produce detectable concentrations of a given marker
were assigned a value of half the limit of detection of that
marker. As the numbers of measurements detectable by
immunoassays were low for interleukin-4 (9.7%, n = 76)
and interferon-γ (20.6%, n = 161), these cytokines were
evaluated as binary variables (i.e., detectable levels versus
levels below the limits of detection); other cord cytokines
and receptors were loge-transformed to obtain approxi-
mately normal distributions (Supplementary Fig. S1).
Study oversight
This study was approved by the US National Institutes of
Health International Clinical Studies Review Committee of
the Division of Microbiology and Infectious Diseases.
Ethical clearance was provided by the Institutional Review
Boards of the Seattle Biomedical Research Institute and
the National Institute for Medical Research in Tanzania.
Participating mothers provided written informed consent
for themselves and their newborn child. Prompt care was
provided to sick children in accordance with Tanzanian
Ministry of Health protocols. All subsequent laboratory
measurements were performed on de-identiﬁed samples.
Statistical analysis
Associations between the baseline risk markers and severe
malarial anemia were quantiﬁed using Cox proportional haz-
ard models. Candidate markers were investigated ﬁrst indi-
vidually using all of the available data for a given marker and
then in combined analyses restricted to those individuals
with complete information. A basic model using the prag-
matic markers of sex, gravidity, transmission season at
delivery, and bed net possession was also explored. Risk dis-
crimination was assessed using Harrell’s C-index, a general-
ization of the area under the receiver operating curve
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suitable for time-to-event analyses [12]. The C-index quan-
tiﬁes the ability of a model to correctly predict the order of
disease events and ranges in value from 0.5 (i.e., chance) to 1
(i.e., perfect prediction of order failure). To investigate the
magnitude of optimism (i.e., overﬁtting of the model due
to the small number of cases and high number of predictors)
[13], bootstrapping was performed using the technique ori-
ginally described by Harrell et al. [14]. For this method, the
data set was resampled to produce 200 replicated data sets.
Then, the prognostic models were ﬁtted to each of the 200
bootstrapped data sets and the original data set. The
C-indices were calculated for all data sets, and the difference
between each resampled data set and the original data set
was recorded. Estimates of optimism were calculated as
the average of the 200 differences. To correct the models,
the optimism estimates were then subtracted from each of
the original C-indices. To elucidate the extent to which
risk prediction might have beneﬁt for public health cam-
paigns against malaria, a modeling exercise was performed
to explore a hypothetical screening program with targeted
versus randomized allocation of antimalarial intervention.
Speciﬁcally, it was assumed that the population had 1000
children, an incidence of severe malarial anemia equivalent
to that observed in the subset of the MOMS Project
cohort with available cord blood cytokine measurements
(n = 781) who were followed between 2002 and 2006,
and resources available to administer an intervention
with 75% protective efﬁcacy [15, 16] to 200 of the
children. All statistical analyses were performed using
Stata – version 12 (StataCorp LP, College Station, TX,
USA).
Results
During a median follow-up of 2.0 (interquartile range, 1.1–
2.9) years, 37 incident severe malarial anemia events were
recorded in the 880 children participating in the MOMS
Project cohort. Out of the baseline demographic and clinical
markers, the transmission season at delivery (evaluated
quarterly) provided the best discrimination of severe malar-
ial anemia risk, and its associated C-index was 0.63 (95% CI
0.54–0.71) (Fig. 1). Household bed net possession at enroll-
ment was also signiﬁcantly predictive in univariate models
with a C-index of 0.61 (95% CI 0.53–0.68) (Fig. 1).
Combining these two predictors with information on the
child’s sex and the mother’s gravidity that are readily obtain-
able at the time of birth yielded an additive C-index of 0.69
(95% CI 0.61–0.77). However, the estimated optimism for
this prognostic model was substantial, and after performing
a bootstrap correction, the C-index remained signiﬁcant but
attenuated to 0.63 (95% CI 0.55–0.71) (Fig. 2).
Out of the cord blood markers, interleukin-1β yielded the
strongest discrimination of risk with a C-index of 0.77 (95%
CI 0.70–0.84) and had an average optimism of only 0.0044
(Figs 1 and 2). In a hypothetical cord blood screening pro-
gram that measures interleukin-1β in 1000 children, the tar-
geted allocation of an intensive antimalarial intervention with
75% efﬁcacy to the top 20% of the population at risk of
severe malarial anemia (i.e., the high risk group) would
avert 13 additional severe malarial anemia events compared
with the distribution of the intervention to a randomly
Table 1. Distribution of baseline characteristics in the MOMS Project
(2002–2006) birth cohort in Muheza, Tanzania
Characteristic Total
n, % or median
(IQR)
Sex 880
Female 423, 48.1%
Male 457, 51.9%
Beta-globin genotype 859
AA 718, 83.6%
AS 141, 16.4%
Alpha-thalassemia genotype 822
α/α 389, 47.3%
α/α− 3.7 336, 40.9%
α− 3.7/α− 3.7 97, 11.8%
Birth weight, kg 880 3.2 (2.9, 3.5)
Maternal age, years 880 25 (20, 30)
Number of previous pregnancies 880 1 (0, 3)
Transmission season at birth 880
Early high transmission season 191, 21.7%
Late high transmission season 240, 27.3%
Early low transmission season 230, 26.1%
Late low transmission season 219, 24.9%
Placental malaria 880
Placental malaria-negative 765, 86.9%
Placental malaria-positive 115, 13.1%
Bed net possession at enrollment
Treated bed net-positive 111, 12.6%
Untreated bed net-positive 344, 39.1%
Bed net-negative/ unknown 425, 48.3%
Intermittent preventive treatment
in pregnancy
820
0 doses 107, 13.1%
1+ doses 713, 87.0%
Tumor necrosis factor, pg/mL 781 121 (69.4, 182)
Tumor necrosis factor – receptor I,
pg/mL
781 2160 (1480, 2880)
Tumor necrosis factor – receptor II,
pg/mL
781 472 (323, 696)
Interleukin – 1β, pg/mL 781 6.00 (3.00, 11.5)
Interleukin – 4 781
Below the limit of detection 705, 90.3%
Detectable 76, 9.7%
Interleukin – 5, pg/mL 781 2.60 (1.00, 5.21)
Interleukin – 6, pg/mL 781 7.00 (2.31, 18.5)
Interleukin – 10, pg/mL 781 3.52 (1.51, 6.04)
Interferon – γ 781
Below the limit of detection 620, 79.4%
Detectable 161, 20.6%
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Fig. 1. Discrimination of severe malarial anemia risk in univariate prognostic models in the MOMS Project (2002– 2006) birth cohort in
Muheza, Tanzania, ranked in order of increasing C-index estimates. IPTP, intermittent preventive treatment in pregnancy; IFN, interferon;
IL, interleukin; TNF-RI, tumor necrosis factor-receptor I; TNF, tumor necrosis factor; TNF-RII, tumor necrosis factor-receptor II.
Fig. 2. Optimism-corrected C-indices for severe malarial anemia risk in the MOMS Project (2002–2006) birth cohort in Muheza,
Tanzania. Abbreviations: IL, interleukin.
cambridge.org/gheg
https://www.cambridge.org/core/terms. https://doi.org/10.1017/gheg.2017.8
Downloaded from https://www.cambridge.org/core. London School of Hygiene & Tropical Medicine, on 05 Mar 2018 at 13:23:31, subject to the Cambridge Core terms of use, available at
selected sample of 20% of the population (Fig. 3). Stratifying
the population’s risk with this 20% cut-off yielded a ROC
area of 0.69 (95% CI 0.61–0.78) (Table 2). Given the total
population prevalence of severe malarial anemia of 4.7%
(95% CI 3.4–6.5%), the positive predictive value (i.e., the
probability that children who received the intensive inter-
vention developed severe malarial anemia) was enriched
to 13.5% (95% CI 8.5–19.8%) in the high risk group, and
the negative predictive value (i.e., the probability that chil-
dren who did not receive the intensive intervention did
not develop severe malarial anemia) remained high at
97.4% (95% CI 95.9–98.5%) (Table 2). In this modeled scen-
ario, the cord blood of 77 (i.e., 1000÷13) children would
have to be screened for interleukin-1β to avert one add-
itional severe malarial anemia case.
Discussion
These data provide proof of concept that a prognostic
model based on measurements captured at the time of
birth can be developed to facilitate the selection of high-risk
children for additional targeted intervention against malaria.
Despite the small sample size and number of cases in this
pilot study, the prognostic associations, particularly with
cord blood cytokines, were strong and had C-indices in
the range of those observed for models of HIV acquisition
[17] and mortality from severe sepsis [18]. Even in the
absence of blood-based measurements, a simple model
based on factors readily obtainable at the time of delivery
(i.e., sex, gravidity, transmission season at delivery, and
bed net possession) was able to correctly predict the severe
malarial anemia order failure for 63 out of 100 pairs of
Fig. 3. Schematic diagram for hypothetical interleukin-1β screening program with targeted allocation of antimalarial intervention.
Table 2. Cord blood interleukin-1β risk scores for severe malarial anemia in the MOMS Project (2002–2006) birth cohort in Muheza, Tanzania (n = 781)
Predicted probability
of severe malarial
anemia by risk
score quintile (%)
No. of
cases/no.
in quintile
Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
ROC area
(95% CI)
Positive predictive
value (%) (95% CI)
Negative predictive
value (%) (95% CI)
Q1 0.5–3.1 0/160 – – – – –
Q2 3.1–3.7 3/153 100 (91–100%) 22 (19–25%) 0.61 (0.59–0.62) 6.0 (4.2–8.1%) 100 (98–100%)
Q3 3.7–4.3 4/156 92 (78–98%) 42 (38–46%) 0.67 (0.62–0.71) 7.3 (5.1–10%) 99 (97–100%)
Q4 4.4–5.3 9/156 81 (65–92%) 62 (59–66%) 0.72 (0.65–0.78) 9.6 (6.6–13%) 97 (96–99%)
Q5 >5.3 21/156 57 (40–73%) 82 (79–85%) 0.69 (0.61–0.78) 13.5 (8.6–20%) 97 (96–99%)
The total population prevalence of severe malarial anemia during the ﬁrst 3 years of life was 4.7% (95% CI 3.4–6.5%). For estimation of
sensitivity, speciﬁcity, ROC area, and positive and negative predictive value, the lower limit of each risk score quintile was used to deﬁne
a ‘positive’ result of the screening test (e.g., Q4, 4.4% predicted probability or higher = positive). Bolded text indicates the performance of
the high risk group cut-off (i.e., top 20%) used in the public health modeling exercise illustrated in Fig. 3.
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children – 13 more pairs than chance alone. Further
research is needed to externally validate the presented
prognostic models of severe malarial anemia risk and to
explore the feasibility of incorporating targeted interven-
tions for high-risk individuals into ongoing antimalarial cam-
paigns in developing countries.
The current study had strengths and limitations. In line
with the recommendations of the TRIPOD statement [19],
candidate predictors were selected to be evaluable both
objectively (and thereby testable in validation cohorts) and
at the time of delivery (i.e., before children would be subject
to interventions that might alter their exposure to
Plasmodium parasites). Minimizing the potential for detection
bias, the outcome of severe malarial anemia was independ-
ently diagnosed by clinical teams prior to the selection of
potential risk predictors. Another strength of this analysis
was that associations between the predictors and outcome
were internally validated using a bootstrap resampling
approach to investigate and correct for overﬁtting that
could arise from the low event to predictor ratio [13].
Moving forward, it will be important to externally validate
the prognostic models for severe malarial anemia in other
birth cohorts. In particular, the generalizability of the
described prediction models may be limited, and it will be
important to validate the models using data from regions
with different ecological patterns of malaria transmission
(e.g., in regions with low or highly seasonal transmission)
where the age of severe malarial anemia onset may be
delayed [20]. In addition, future studies should aim to recruit
larger sample sizes with greater numbers of severe malaria
cases in order to mitigate optimistic model performance
estimates. Including more participants will also enable inves-
tigations of the potential heterogeneity in the model’s dis-
crimination that may exist within clinically relevant
sub-groups (e.g., in children exposed to placental malaria
in utero).
In regions that are approaching the elimination of malaria,
identifying high risk groups based on easily ascertainable and
low cost indicators will be particularly relevant, and efforts
should be made to enhance the feasibility of malaria screen-
ing programs. Speciﬁcally, future studies that aim to formally
develop prognostic models of life-threatening malaria in
childhood should evaluate additional pragmatic predictors,
such as parental occupation (e.g., working in the logging
industry [21]) and housing conditions (e.g., the presence
of window and door screens) [22, 23]. Investigations into
the cost-effectiveness of a potential screening program
should also consider alternative assays for evaluating children’s
blood-based biomarkers (e.g., use of dried blood spots [24])
as well as factors that could inﬂuence the context-speciﬁc
protective efﬁcacy of interventional programs (e.g., relative
abundance of drug-resistant parasites [25]).
In conclusion, this study provides valuable new evidence
that the development of a prognostic model for severe mal-
arial anemia during infancy and early childhood is
scientiﬁcally plausible. By providing clinicians and families
with an objectively estimated probability of a newborn’s
risk of developing life-threatening complications of infection,
personalized medicine approaches have the potential to
complement on-going population-wide approaches for mal-
aria prevention.
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